Portal de Periódicos da CAPES

Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China

2017; Impact Journals LLC; Volume: 8; Issue: 9 Linguagem: Inglês

10.18632/oncotarget.14706

1949-2553

Yongchun Zhou, Yanlong Yang, Chenggang Yang, Yunlan Chen, Changshao Yang, Yaxi Du, Guangqiang Zhao, Yinjin Guo, Lianhua Ye, Yunchao Huang,

Cholangiocarcinoma and Gallbladder Cancer Studies

// Yongchun Zhou 1, * , Yanlong Yang 2, * , Chenggang Yang 3, * , Yunlan Chen 4 , Changshao Yang 5 , Yaxi Du 5 , Guangqiang Zhao 2 ,Yinjin Guo 5 , Lianhua Ye 2 , Yunchao Huang 1, 2 1 Tumor Research Institute of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University (Yunnan Tumor Hospital), Kunming, 650118, PR China 2 Department of Thoracic Surgery I, The Third Affiliated Hospital of Kunming Medical University (Yunnan Tumor Hospital), Kunming, 650118, PR China 3 Department of Pathology, The Third Affiliated Hospital of Kunming Medical University (Yunnan Tumor Hospital), Kunming, 650118, PR China 4 Cadre Ward, The Third Affiliated Hospital of Kunming Medical University (Yunnan Tumor Hospital), Kunming, 650118, PR China 5 Key Laboratory of Lung Cancer Research of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, PR China * These authors contributed equally to this work Correspondence to: Yunchao Huang, email: hycyn2008@163.com Keywords: non-small cell lung cancer, EGFR mutation, cftDNA, Yunnan, Xuanwei Received: September 22, 2016 Accepted: November 18, 2016 Published: January 17, 2017 ABSTRACT To investigate the Epidermal Growth Factor Receptor (EGFR) mutation status in non-small cell lung cancer (NSCLC) in Yunnan province in southwestern China, we detected EGFR mutation by Amplification Refractory Mutation System (ARMS) polymerase chain reaction (PCR) using DNA samples from 447 pathologically confirmed NSCLC specimens (175 tissue, 256 plasma and 16 cytologic samples). The relationship between EGFR mutations and demographic and clinical factors were further explored. Subgroup analyses according to sample type (tissue and plasma) and histological type (adenocarcinoma) were done. We found the mutation rate was 34.9% in overall patients (42.3%, 29.7%, and 37.5% for tissue, plasma, and cytologic samples respectively). We found female ( p < 0.0001), no smoking ( p = 0.001), adenocarcinoma ( p < 0.0001), and tissue specimen ( p = 0.026) were associated with higher EGFR mutation rate. The most common mutations were exon 19 deletions (40%) and L858R point (30%) mutation. Interestingly, NSCLC patients from Xuanwei harbored a strikingly divergent mutational pattern for EGFR when compared with non-Xuanwei patients (higher G719X, G719X+S768I mutations, but lower 19 deletion and L858R mutations). Generally, EGFR mutation rate and pattern in Yunnan province was in accord with other Asian populations. However, Xuanwei subgroup showed strikingly divergent EGFR mutation spectrum from other general population. Our analysis also indicated that cftDNA analysis for EGFR mutations detection was feasibility for the patients lacking sufficient tissue for molecular analyses.